Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

NCT02993094 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Due to slow recruitment, the study had to be terminated prematurely.

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Ixazomib
DRUG: Carboplatin

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]